Welcome to our dedicated page for Pulsenmore news (Ticker: PLSM), a resource for investors and traders seeking the latest updates and insights on Pulsenmore stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulsenmore's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulsenmore's position in the market.
Pulsenmore (NASDAQ: PLSM) reported full-year 2025 revenue of $12.5 million, a 374% increase versus 2024, driven largely by a $9.6 million one-time settlement with GE. Net loss improved to $5.0 million from $10.0 million in 2024. Total liquid assets were $21.7 million (including $7.0 million cash) as of Dec 31, 2025.
Key operational milestones include FDA clearance for remote-use prenatal ultrasound in the U.S., MDR/CE certification for the Pulsenmore Early-Screening pregnancy product in Europe, and initial U.S. commercial programs. Management will host a webcast today, March 30, 2026, at 8:30am ET to discuss results and business update.
Pulsenmore (NASDAQ: PLSM) will release full year 2025 financial results on March 30, 2026 at 8:30 a.m. Eastern Time and will host a conference call and webcast to review results, business highlights, and recent progress.
Management presenting includes Jonathan Adereth (Chairman), Dr. Elazar Sonnenschein (CEO), Eran Hirsh (CFO), and Mira Altmark-Sofer (VP Marketing). The live webcast link and replay will be available on the company's Investor Relations website.
Pulsenmore (NASDAQ: PLSM) announced a commercial services agreement with TLC Perinatal PA to incorporate Pulsenmore's Early Screening home ultrasound into a physician-directed hybrid prenatal care pathway in Maryland.
The agreement covers Silver Spring and Germantown sites and aims to combine home ultrasound, telehealth, and scheduled clinic visits to extend care beyond the clinic.
Pulsenmore (NASDAQ: PLSM) announced its first U.S. commercial engagement on Feb 2, 2026, following FDA clearance for its home pregnancy ultrasound product. The company signed a services agreement with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles to provide Pulsenmore ES home ultrasound services.
The agreement enables remote prenatal monitoring for patients at a center that manages approximately 1,500 pregnancies per year, with the goal of reducing unnecessary diagnostic visits and expanding telehealth-driven prenatal care.
Pulsenmore (NASDAQ: PLSM) and Clalit Health Services signed a strategic commercial agreement to deploy Pulsenmore FC, an at-home follicular monitoring service, via Beilinson NEXT in Israel. The agreement is potentially valued at $4.5 million over five years following an 18‑month pilot, with ramp-up expected in the coming weeks. Pulsenmore will supply patient‑operated devices, a mobile app with real‑time guidance, and secure image transmission for remote clinical oversight. A June 2025 study at Beilinson reported a strong safety profile and high concordance with in‑clinic measurements. Pulsenmore ES holds FDA De Novo authorization and a separate binding order for 25,000 units was signed in October 2024. Pulsenmore FC is approved for commercial use in Israel.
Pulsenmore (NASDAQ: PLSM) began trading on Nasdaq at the U.S. market open on January 21, 2026 and will also trade on the Tel Aviv Stock Exchange. The company develops physician-supervised home prenatal ultrasound and telehealth technology combining proprietary hardware, secure cloud image transmission, and clinical review workflows.
Pulsenmore has received FDA authorization for its home-use prenatal ultrasound system, providing a regulatory foundation for potential U.S. commercialization as the company says it accelerates expansion and engagement with U.S. medical centers.